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Summary
Phosphorylation of translation initiation factor 2a (eIF2a) coordinates a translational and transcriptional program known as
the integrated stress response (ISR), which adapts cells to endoplasmic reticulum (ER) stress. A screen for small molecule
activators of the ISR identified two related compounds that also activated sterol-regulated genes by blocking cholesterol
biosynthesis at the level of CYP51. Ketoconazole, a known CYP51 inhibitor, had similar effects, establishing that perturbed
flux of precursors to cholesterol activates the ISR. Surprisingly, compound-mediated activation of sterol-regulated genes
was enhanced in cells with an ISR-blocking mutation in the regulatory phosphorylation site of eIF2a. Furthermore, induction
of the ISR by an artificial drug-activated eIF2a kinase reduced the level of active sterol regulatory element binding protein
(SREBP) and sterol-regulated mRNAs. These findings suggest a mechanism by which interactions between sterol metabo-
lism, the ISR, and the SREBP pathway affect lipid metabolism during ER stress.Introduction
Phosphorylation of the a subunit of eukaryotic translation initia-
tion factor 2 on serine 51 adapts mammalian cells to a variety
of stressful conditions (Hinnebusch, 1994; Dever, 2002). eIF2a
phosphorylation promotes a stress-resistant state by global at-
tenuation of protein synthesis, which reduces the load of un-
folded proteins on chaperone networks and diverts amino acids
from energetically costly protein synthesis to other metabolic
pathways. In addition to these general effects on protein and
amino acid metabolism, eIF2a phosphorylation also activates
a gene-expression program that depends in part on the transla-
tional upregulation of the transcription factor ATF4 (Harding
et al., 2000a; Lu et al., 2004a). This stereotyped response, cen-
tered on eIF2a phosphorylation, is activated by diverse stressful
conditions and is therefore referred to as an integrated stress re-
sponse (ISR) (Harding et al., 2003).
Four different kinases are known to phosphorylate eIF2a, and
each responds to a distinct upstream activation signal. Amino
acid starvation activates the ISR through GCN2, a kinase con-
served from yeast to mammals (Hinnebusch and Natarajan,
2002). Viral infection and iron deficiency activate the ISR through
the vertebrate-specific kinases PKR (Kaufman, 2000) and HRI
(Chen, 2000), respectively, whereas stress from accumulation
of unfolded or misfolded proteins in the endoplasmic reticulum
(ER stress) activates the ISR through the ER-localized PERK ki-
nase (Harding et al., 1999).CELL METABOLISM : DECEMBER 2005 $ VOL. 2 $COPYRIGHT ª 2005A single point mutation that precludes eIF2a phosphorylation
(eIF2aS51A) sensitizes cells to a wide variety of stressful condi-
tions (Scheuner et al., 2001), whereas loss of specific eIF2a
kinase function sensitizes cells selectively to cognate stress.
The phenotype associated with loss of the ER-stress-inducible
eIF2a kinase PERK is especially severe, as it leads to dysfunc-
tion and destruction of multiple secretory cells (Harding et al.,
2001; Zhang et al., 2002). The ISR is thus important for dealing
with physiological levels of ER stress, and it constitutes one of
the three known components of the unfolded protein response
(UPR) (Mori, 2000). The UPR’s two other components are medi-
ated by the ER-membrane-associated kinase IRE1 and its
downstream effector, the transcription factor XBP-1, and by
the ER-membrane bound transcription factor ATF6. Collectively
PERK, IRE1, and ATF6 regulate the load of ER client proteins
and the cellular apparatus that copes with that load (Mori,
2000; Patil and Walter, 2001; Kaufman, 2002).
The signaling pathway that controls sterol metabolism in
mammalian cells is also organized around an ER nexus and is
known to share components with the ER-stress-responsive
pathways described above (Brown et al., 2000; Ye et al., 2000).
Furthermore, there is mounting evidence for a measure of over-
lap in the readouts of pathways that respond to ER stress and
sterol depletion (Cox et al., 1997; Ron and Hampton, 2004; Sri-
buri et al., 2004). Here we report on a screen for small molecule
activators of the ISR that revealed hitherto unsuspected links be-
tween sterol synthesis, sterol-mediated signaling, and the ISR.ELSEVIER INC. DOI 10.1016/j.cmet.2005.11.005 361
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Identification of small molecule activators of the ISR
To screen for compounds that activate the ISR, a reporter cell
line was created by stably transfecting CHO-K1 cells with a fu-
sion of the regulatory sequences from the ISR-inducible CHOP
gene (Novoa et al., 2001) and a luciferase reporter (Figure 1A).
The reporter gene was activated by thapsigargin and tunicamy-
cin, agents that cause ER stress and activate the ISR through
PERK, and by proteotoxic/oxidative stress induced by sodium
arsenite, as expected (Figure 1B). Three thousand compounds
from a space-filling combinatorial library (Khersonsky et al.,
2003;Uttamchandani et al., 2005)were screenedat a concentra-
tion of 10 mM in a 96-well format. Two structurally related com-
pounds, TGD31 and TGD45, reproducibly induced the reporter
w2-fold when added to the culture media (data not shown).
Benzoyl-modified derivatives of these compounds (NH2/
NHBz) with increased cell permeability were synthesized.
TGD31BZ and TGD45BZ proved to be more potent activators
of the ISR reporter gene than the parent compounds (Figures
1C and 1D) and, because of their indistinguishable activity pro-
file and structural similarity, were used interchangeably for sub-
sequent studies.
To determine whether these compounds also activated en-
dogenousmarkers of the ISR, wemeasured the levels of endog-
enous phosphorylated eIF2a, ATF4, and CHOP in compound-
treated cells. The compound-dependent increase in activity of
all three markers observed in wild-type mouse embryonic fibro-
blasts was blocked by a mutation (eIF2aS51A) that eliminates the
regulatory phosphorylation site (Scheuner et al., 2001), indicat-
ing that CHOP and ATF4 induction depended on eIF2a phos-
phorylation (Figure 2A). The essential role of eIF2a phosphoryla-
tion in mediating the biological effects of the compounds was
further substantiated by gene-expression profiling, which re-
vealed that the eIF2aS51A mutation blocked the induction of
most of their target genes (Figure 2B; see also Table S1 in the
Supplemental Data available with this article online). Only 21
of the 157 genes whose mRNA levels increased more than
2-fold in compound-treated wild-type cells were also inducible
in the mutant. Furthermore, most of the eIF2a-phosphorylation-
independent genes (induced by the compounds in both wild-
type and eIF2aS51A mutant cells) were not previously identified
as ISR targets (Harding et al., 2003; Lu et al., 2004b); the signif-
icance of this last observation will be clarified below.
Next we examined the activity of individual eIF2a kinases in
compound-treated cells. GCN2, the highly expressed eIF2a
kinase responsive to amino acid starvation, remained inactive
in compound-treated cells, as measured by reactivity to a
phospho-GCN2 antiserum.However, PERKactivity asmeasured
Figure 1. Identification of chemical activators of the integrated stress response
A) Cartoon depicting the structure of the CHOP::luciferase reporter. The CHOP
gene is fused to the luciferase protein coding region at exon 3, immediately up-
stream of the start codon.
B) Fold increase of the luciferase activity of a CHOP::luciferase-expressing stable
CHO cell line after 16 hr exposure to thapsigargin (Tg), sodium arsenite (Ars), or tu-
nicamycin (Tm). The mean 6 range of luciferase activity normalized for protein
content in duplicate samples is displayed.
C) Fold increase in luciferase activity of the aforementioned cell line following 16 hr
exposure to the benzoyl-modified derivatives of the two ISR activators identified in
our screen (TGD31 and TGD45). Luciferase activity of cells exposed to the known
ISR inducer tunicamycin is provided as a reference.
D) Chemical structure of TGD31BZ and TGD45BZ.CELL METABOLISM : DECEMBER 2005
CYP51 inhibition and the ISRby the phosphorylation-dependent decrease in the protein’s
mobility on SDS-PAGE (Harding et al., 1999) was modestly but
reproducibly enhanced in compound-treated cells (Figure 2C).
This observation suggests that the compounds cause some
level of ER stress; however, the magnitude of that perturbation
Figure 2. Compound-mediated ISR activation requires eIF2a phosphorylation
and correlates with activation of PERK
A) Immunoblots of phosphorylated eIF2a (eIF2a-P), total eIF2a, ATF4, and CHOP
from wild-type and mutant eIF2aS51A cells that were untreated or treated with so-
dium arsenite (Ars) or 35 mM TGD45BZ for 4, 8, or 16 hr.
B) Relative expression levels of the subset of genes induced at least 2-fold by
TGD45BZ in wild-type cells compared to their level of expression in identically
treated eIF2aS51A mutant cells. ‘‘Expression level’’ is defined as the ratio of the av-
erage signal strength of each gene at each time point to the median signal strength
of that gene derived from all experimental time points.
C) Immunoblots of CHOP, GCN2, and PERK from extracts of wild-type and
eIF2aS51A cells that were untreated or treatedwith tunicamycin (Tm), medium lack-
ing nonessential amino acids and leucine (2NEAA, Leu), or 35 mM TGD45BZ for 4,
8, or 16 hr. CHOPwas detected by immunoblot of nuclear extracts, whereas GCN2
and PERK were immunoprecipitated first from detergent-solubilized cell lysates.
The GCN2 immunoprecipitates were sequentially reacted with antisera specific
to the phosphorylated form of GCN2 (GCN2-P) and then total GCN2, whereas
PERK immunoprecipitates were probed with antisera that recognize both the
phosphorylated (PERK-P) and nonphosphorylated forms of the protein.CELL METABOLISM : DECEMBER 2005is modest compared with potent activators of the ER stress re-
sponse (such as tunicamycin) as it did not lead to activation of
other ER stress pathways, such as XBP-1 processing (Fig-
ure S1A).
Due to its low level of expression in fibroblasts, we were
unable to assay HRI activation, but PKR, which was readily in-
duced by viral infection in these cells, was not measurably acti-
vated by TGD45BZ (negative data not shown). Despite these
observations, which point selectively to PERK activation by
the compounds, ISR markers remained inducible in Perk2/2
(and Pkr2/2, Gcn22/2, and Hri2/2) MEFs. Thus, no single
eIF2a kinase was required for the induction of the ISR by the
compound (Figure S1B). The compounds thus promote the
ISR by both activation of PERK and additional mechanisms
that function in the absence of that kinase.
Consistent with experiments conductedwith other ISR activa-
tors (Jousse et al., 2003; Lu et al., 2004b), we found that pre-
treatment with TGD31BZ (or TGD45BZ) strongly protected
HT22 cells from oxidative glutamate toxicity and hadmoremod-
est protective effects against stress induced by protein misfold-
ing induced by tunicamycin or azetadine-2-carboxylic acid (Fig-
ures S2C and S2D). The pervasive role of eIF2a phosphorylation
in compound-mediated gene activation (Figure 2B) led us to ex-
pect that their protective effects would also be blocked by the
eIF2aS51A mutation. Surprisingly, the compounds specifically
protected the eIF2aS51A mutant cells against tunicamycin (Fig-
ures 3A and 4E), and the magnitude of the protective effect
was greater in the mutant cells than in the wild-type (compare
Figures S2D and S2E with Figure 3A).
Faced with this evidence for ISR-independent effects of the
compounds, we scrutinized more closely the gene-expression
profile of compound-treated mutant cells. As expected, no
ISR target genes were induced by TGD31BZ in the mutant cells
(Figure 2B and Table S1). However, the compound coordinately
induced a set of genes involved in cholesterol and fatty-acid bio-
synthesis. A significant overlap was noted between this ISR-
independent set of compound target genes and genes previously
identified as targets of sterol-activated transcription factors
(SREBPs; sterol regulatory element binding proteins) (Horton
et al., 2003) (Tables S2 and S3). Furthermore, this class of genes
was expressed at lower levels in compound-treated wild-type
compared to eIF2aS51A mutant cells (Figure 3B). Northern blot
analysis of two representative SREBP target genes (iso-
pentenyl-diphosphate delta-isomerase 1, IDI1, and sterol-C4-
methyl oxidase-like, SC4MOL) revealed that both were regu-
lated in a biphasic manner by compound in wild-type cells,
whereas their mRNAs increased monotonically with compound
dose in the eIF2aS51A mutant cells (Figure 3C).
SREBPs are activated by a well-characterized posttransla-
tional proteolytic processing step triggered by cholesterol de-
pletion (Hampton, 2002; Rawson, 2002). To determine whether
TGD31BZ accesses this canonical pathway, we followed
SREBP1 and SREBP2 processing by immunoblot, which distin-
guishes the larger unprocessed ER-membrane-associated pre-
cursor from the smaller, processed, active form. In cholesterol-
replete cells, most of the SREBP1 and SREBP2was found in the
inactive precursor form. Both mevastatin (an inhibitor of choles-
terol biosynthesis) and TGD31BZ increased the level of acti-
vated SREBPs (Figures 3D and 3E). The level of SREBP precur-
sor also increased in treated cells, which is expected as SREBPs
positively regulate their own expression (Horton et al., 2003).363
A R T I C L EFigure 3. TGD31BZ and TGD45BZ protect cells against tunicamycin and induce SREBP target genes independently of eIF2a phosphorylation
A) Survival and growth of eIF2aS51A mutant fibroblasts pretreated for 14 hr with the indicated dose of TGD31BZ or TGD45BZ followed by subsequent challenge with 0, 50,
100, 200, or 400 ng/ml tunicamycin (Tm) for 24 hr. Survival is expressed as relative amount of WST reduced by cells compared to the untreated (first column, which is set
arbitrarily at 1). Values shown are the mean 6 range from a representative experiment performed in duplicate and reproduced twice.
B) Relative expression levels of genes previously identified as SREBP target genes (Horton et al., 2003) in wild-type and eIF2aS51A cells following 8 or 16 hr of TGD45BZ
treatment.
C) Northern blot analysis of the isopentenyl-diphosphate delta-isomerase1 (IDI1), sterol-C4-methyl oxidase-like (SC4MOL), CHOP, and GAPDH genes in cells with the
indicated genotypes treated for 19 hr with compound.
D) Immunoblot of SREBP1 from sterol-replete cells or cells treated with the indicated concentration of mevastatin (a known inhibitor of cholesterol biosynthesis) or
TGD31BZ. The position of the inactive transmembrane SREBP1 precursor and the active, cleaved amino-terminal fragment of SREBP1 are indicated. The TLS immunoblot
serves as loading control.
E) Immunoblot of SREBP2 from wild-type cells treated as in (D).364 CELL METABOLISM : DECEMBER 2005
CYP51 inhibition and the ISRFigure 4. TGD31BZ and TGD45BZ inhibit cholesterol synthesis at the level of lanosterol demethylation and attenuate the inhibitory effects of tunicamycin on protein gly-
cosylation
A) Total cholesterol levels in nonsaponifiable lipid extracts of cells cultured in lipoprotein-deficient serum with no additions (UT), supplemented with sterols and sterol pre-
cursors (MOC = mevalonate + oleic acid + cholesterol), or treated with 6 or 12 mM TGD31BZ or 50 mM mevastatin for 24 hr. The mean 6 range of duplicate samples is
displayed.
B) Diagram of the lipid and sterol biosynthetic pathway (Gardner et al., 2001) and the site of action of inhibitors used in this study.
C) Autoradiogram of a thin-layer chromatograph of nonsaponifiable lipids isolated from cells labeled with [14C]mevalonate for 5 hr following pretreatment for 1 hr with the
indicated concentration of TGD31BZ, 31 mMRO 48-8071, 31 mM TGD45BZ, or 62 mMNB-598. The migration of the various cholesterol precursors and their metabolites is
indicated to the left of the autoradiogram: squalene (S), squalene 2,3-oxide (SO), squalene 2,3:22,23-dioxide (SDO), lanosterol (Lano), dihydrolanosterol (D-lano), and cho-
lesterol (Chol). The fraction of the label incorporated into lanosterol and cholesterol in each lane is presented below the autoradiogram.
D) Autoradiogram of 35S-labeled HSP47 immunoprecipitated from untreated mutant eIF2aS51A cells and following pretreatment with 12 mM TGD31BZ or 40 mM
ketoconazole (Keto) for 17 hr prior to the addition of the indicated concentration of tunicamycin (for 6 hr) followed by a 60 min pulse of [35S]methionine-cysteine.
E) Survival and growth of mutant eIF2aS51A fibroblasts pretreated for 14 hr with the indicated concentration of TGD31BZ, ketoconazole (Keto), TGD45BZ, or mevastatin (M)
followed by subsequent challenge with 300 ng/ml tunicamycin (+TM, filled bars) or vehicle (2TM, open bars). Survival is expressed as relative amount of WST reduced by
cells compared to the untreated (first column, which is set arbitrarily at 1). Values shown are themean6 range from a representative experiment performed in duplicate and
reproduced twice.Furthermore, SREBP activation in compound-treated wild-type
cells was also biphasic, decreasing with the higher concentra-
tions of compound that are associated with ISR activation.
This decrease was not observed in eIF2aS51A mutant cells
(Figure 3D). These observations implicate the SREBPs in
compound-mediated gene activation and suggest that inhibition
of IDI and SC4MOL gene expression at higher doses, observedCELL METABOLISM : DECEMBER 2005only in the wild-type cells, could be due to ISR-dependent re-
pression of SREBP activation (Figures 3C–3E).
The similarities in SREBP activation noted above in mevasta-
tin- and compound-treated cells suggested that the latter, too,
might inhibit one of the enzymes involved in cholesterol bio-
synthesis. In support of this idea, we found that activation of
SREBP1 and SREBP2 by TGD31BZ (and mevastatin) correlated365
A R T I C L Ewith diminished cellular cholesterol content (Figure 4A). To map
a possible site for inhibition of cholesterol biosynthesis, we
labeled cells with 14C-mevalonate and used thin-layer chroma-
tography to follow the accumulation of its metabolites in cells
treated with various compounds. Cholesterol and its immediate
precursors dihydrolanosterol and lanosterol were the only la-
beled species detectable by this assay in untreated cells, with
most of the label accumulating in the final product, cholesterol
(Figures 4B and 4C). Treatment with TGD31BZ led to a dose-
dependent increase in the fraction of label retained in the
lanosterol precursor, suggesting that the compounds block cho-
lesterol biosynthesis at the level of CYP51, the enzyme that de-
methylates lanosterol. Qualitatively similar observations were
made in cells treated with TGD45BZ. As controls, we treated
cells with established inhibitors of cholesterol biosynthesis, RO
48-8071 or NB-598, and found accumulation of intermediates
predicted by their known sites of inhibition (Figures 4B and 4C).
The block in cholesterol biosynthesis explains the activation
of sterol-regulated signaling pathways by the novel compounds
and also suggests how they might protect eIF2aS51A mutant
cells, specifically against tunicamycin: Dolichol, the lipid anchor
on which carbohydrate chains are assembled before their trans-
fer to asparagine residues on glycoproteins, is synthesized from
farnesyl pyrophosphate, an intermediate in the cholesterol
biosynthetic pathway (Faust et al., 1980; Goldstein and Brown,
1990) (Figure 4B). Furthermore, mevalonate is limiting for doli-
chol synthesis and subsequent glycosylation (Carlberg et al.,
1996). Thus, interrupting the flow of precursors to cholesterol
downstream of farnesyl pyrophosphate might redirect them to
the production of dolichol, which would counteract the inhibitory
effects of tunicamycin on N-linked glycosylation by increased
substrate availability. To test this hypothesis, we compared tu-
nicamycin-mediated inhibition of glycosylation of an endoge-
nous model glycoprotein, HSP47 (Nagata et al., 1988), in un-
treated and compound-treated cells. At a given concentration
of tunicamycin, less underglycosylated HSP47 was noted in
cells treated with either TGD31BZ or ketoconazole (a structur-
ally unrelated azole inhibitor of CYP51; Ito et al., 1994) (Fig-
ure 4D). These effects on glycosylation were mirrored by keto-
conazole’s ability to protect eIF2aS51A mutant cells against the
lethal effects of tunicamycin (but not thapsigargin, which in-
duces ER stress by the unrelated mechanism of calcium de-
pletion; Figure 4E and Figures S2D and S2E). By contrast, me-
vastatin, which inhibits cholesterol biosynthesis upstream of
farnesyl pyrophosphate, had no protective effect (Figure 4E).
These results suggest that the compound protects cells against
tunicamycin by diverting precursors to dolichol synthesis rather
than by cholesterol depletion or SREBP activation.
Interactions between sterols, ER stress, and the ISR
To determine whether activation of the ISR by the compounds
was mimicked by known inhibitors acting at the same step in
cholesterol biosynthesis, we treated cells with the CYP51 inhib-
itor ketoconazole. As expected, the SREBP target genes IDI1
and SC4MOL were induced by ketoconazole. Importantly, the
ISR target gene CHOP was strongly induced in wild-type cells
and to much lower levels in the eIF2aS51A mutants. Activation
of the SREBP target genes declined at concentrations of keto-
conazole that induced CHOP, mirroring the profile of TGD31BZ
(Figures 5A and 3C). This reciprocal relationship of the ISR and
sterol-regulated gene expression was dependent on eIF2a366phosphorylation as it was not observed in eIF2aS51A mutant
cells (Figures 5A and 3C). Furthermore, like our compounds, ke-
toconazole also activated PERK (Figure 5B) but did not induce
XBP-1 processing (Figure 5C), indicating equivalence in their
biological effects in this system.
To directly examine the role of eIF2a phosphorylation in inhi-
bition of SREBP target genes, we exploited an experimental
system that uncouples eIF2a phosphorylation from ER stress
and changes in cellular calcium metabolism. The system con-
sists of cells stably expressing a ligand-activatable chimeric
eIF2a kinase, Fv2E-PERK, in which kinase activity is subordi-
nate to an otherwise inert, small, cell-penetrant dimerizer drug,
AP20187 (Figure 6A) (Lu et al., 2004b). Addition of AP20187
ligand activated the chimeric Fv2E-PERK kinase and its ISR
target gene CHOP in a dose-dependent manner, as expected
(Lu et al., 2004b). However, basal levels of the SREBP target
mRNAs, ID1, and SC4MOL declined progressively, exhibiting
an inverse relationship to ISR activity (Figure 6B). The Fv2E-
PERK-mediated ISR antagonized not only the basal expression
of SREBP target genes but also their mevastatin-induced acti-
vation (Figure 6C). This antagonism correlates with an ISR-
mediated inhibition of SREBP activity as reflected by lower
Figure 5. Ketoconazole mimics the effect of TGD compounds
A) Northern blot analysis of the sterol-regulated genes isopentenyl-diphosphate
delta-isomerase1 (IDI1) and sterol-C4-methyl oxidase-like (SC4MOL), the ISR
marker CHOP, and the loading control GAPDH in total RNA from cells with the in-
dicated eIF2a genotypes that were incubated in the presence of sterols (c) or oleic
acid (o) or treated for 24 hr with the indicated concentration of ketoconazole.
B) Immunoblot of PERK, immunoprecipitated from untreated cells or cells treated
with ketoconazole or tunicamycin (2.5 mg/ml for 4 hr as a positive control). The
phosphorylated (P-PERK) and nonphosphorylated forms are indicated.
C) Ethidium-stained gel of XBP-1 RT-PCR of RNA isolated from untreated cells or
cells treated with 2 mg/ml tunicamycin or the indicated dose of ketoconazole for
24 hr. The position of the cDNAs derived from the unprocessed (XBP-1u) or pro-
cessed (XBP-1p) mRNAs is indicated.CELL METABOLISM : DECEMBER 2005
CYP51 inhibition and the ISRFigure 6. ISR activation inhibits sterol-regulated
gene expression by inhibiting SREBP activation
A) Cartoon depicting the ligand-activated Fv2E-
PERK. The AP20187 ligand binding domain is fused
to PERK’s eIF2a kinase domain that is activated by
addition of the ligand to the culture media.
B) Northern blot analysis of samples from untreated
Fv2E-PERK-expressing CHO cells or cells in which
the ISR was activated by AP20187 (10 nM) for 1, 2,
4, or 8 hr. Mevastatin (25 mM) serves as a positive
control.
C) As in (B) except that the cells were treated with
mevastatin (25 mM) for 16 hr with or without
AP20187 ligand (at 1, 2, 4, 8 nM).
D) Immunoblot of SREBP1 and phosphorylated
Fv2E-PERK or total Fv2E-PERK from sterol-replete
cells or cells treated with 25 mM mevastatin alone
or with the indicated concentrations of AP20187.
The inactive SREBP1 precursor and the active
amino-terminal fragment from the same gel are
shown in separate panels. Total eIF2a was used as
a loading control.
E) Total cholesterol in nonsaponifiable lipid extracts
of Fv2E-PERK-expressing CHOcells cultured in lipo-
protein-deficient serum with no additions, supple-
mented with lipid-containing whole serum, or treated
with the indicated concentrations of AP20187 or
TGD31BZ for 24 hr. The mean and SEM of triplicate
samples is displayed.
F) Comparison of the effects of ISR activation on cell
growth in media containing complete serum or se-
rum lacking lipoproteins (LPDS). Plotted is the ratio
of Fv2E-PERK-expressing CHO cells following 96
hr of culture in the presence of the indicated concen-
tration of AP20187 compared with the untreated
cells (set at 100%). The inset panel shows the growth
of parental CHO cells lacking Fv2E-PERK under the
same conditions. The mean and SEM of triplicate
samples is displayed.levels of processed SREBP1 in AP20187-treated cells (Figure
6D). Furthermore, this antagonism at the level of SREBP activa-
tion depended on eIF2a phosphorylation, as it was not evident in
Fv2E-PERK-expressing eIF2aS51A mutant cells (Figure S3).
ISR-mediated inhibition of SREBP target genes was also as-
sociated with a dose-dependent decrease in cellular cholesterol
content (Figure 6E). Furthermore, induction of the ISR preferen-
tially compromised cell growth in lipoprotein-deficient serum,
compared to lipoprotein-containing whole serum (Figure 6F).
Together, these observations indicate that the ISR inhibits theCELL METABOLISM : DECEMBER 2005sterol-regulated gene expression program at the level of SREBP
activation and that this limits the ability of cells to produce cho-
lesterol and grow in cholesterol-deficient medium.
Discussion
Here we have described a screen for small molecule activators
of the integrated stress response (ISR), which led to the discov-
ery of hitherto unsuspected interactions between sterol biosyn-
thetic pathways and the unfolded protein response: Blocking367
A R T I C L EFigure 7. Cartoon depicting relationships between
TGD31/45, cholesterol biosynthesis, and the ISR
TGD31/45 block lanosterol demethylation, a late
step in cholesterol biosynthesis, and thereby acti-
vate the ISR, perhaps through the accumulation of
a toxic precursor. The ISR inhibits SREBP activation
by an unknown mechanism that likely requires ISR
target-gene activation. These could encode a direct
protein repressor of SREBP activation or could re-
press SREBP indirectly—for example, by altering
membrane lipid composition. At the same time, the
block in cholesterol biosynthesis diverts precursors
to dolichol and thereby attenuates tunicamycin-
mediated ER stress. By an unknown mechanism,
TGD31/45 also activate the ISR independently of
their ability to cause ER stress and activate PERK.
We speculate that the ISR-mediated inhibition of
SREBP activation fine tunes sterol biosynthesis to
the circumstances of ER-stressed cells.cholesterol biosynthesis at the level of lanosterol demethylation
activates the eIF2a-phosphorylation-dependent arm of the UPR
(the ISR), and the ISR inhibits sterol-regulated gene expression
by blocking SREBP activation. These findings are important to
our understanding of lipids’ role in ER homeostasis and the
role of ER stress signaling in lipid metabolism.
Two related ISR activators, TGD31 and TGD45, were found to
inhibit lanosterol demethylation, which is carried out by the P450
enzyme CYP51. ISR activation is likely to be linked mechanisti-
cally to inhibition of this step in cholesterol biosynthesis as
a structurally unrelated compound, ketoconazole, which targets
the same enzyme, also activates the ISR. A significant role
for apoptosis in compound-mediated activation of SREBPs
(Wang et al., 1996) is disfavored by the observation that, at the
doses required to activate SREBPs, the compounds do not pro-
mote cell death (compare Figures 3D and 3E with Figure S4).
Interfering with the flux of metabolites to cholesterol has the
predicted consequence of depleting the end product and results
in lower cholesterol content of cells growing in lipoprotein-
deficient media. However, our study also suggests that interfer-
ence with CYP51 leads to significant accumulation of sterol-
pathway precursors: Both compounds, and ketoconazole,
markedly protected cells against the glycosylation inhibitor tuni-
camycin, an effect that was more striking in the eIF2aS51A cells
that are hypersensitive to ER stress (Scheuner et al., 2001).
The compounds achieved this by attenuating the toxin’s ability
to block N-linked glycosylation (Lehrman et al., 1988; Zhu
et al., 1992). These observations are consistent with diversion
of cholesterol precursors accumulating upstream of the block
to the synthesis of dolichol and an increased pool of lipid-
anchored oligosaccharides in compound-treated cells. It is un-
clear if competition for cholesterol precursors ever limits the ca-
pacity for ER glycosylation in physiological circumstances, but
our study points to an equilibrium in the partitioning of choles-
terol precursors between different fates that can be perturbed
to affect protein glycosylation and perhaps other processes
(Figure 7).
Recent evidence suggests that abnormally high free-
cholesterol content of the ER membrane negatively affects or-
ganelle homeostasis (Feng et al., 2003; Li et al., 2004). We found
that the TGD compounds that deplete cellular cholesterol stores
and activate the ISR also do so by promoting ER stress (at least368in part, as reflected by PERK activation). Thus it appears that the
protein folding environment in the ER is sensitive to both ex-
tremes in cholesterol content of the cell. It is also possible that
an accumulating precursor or product (or products) of a parallel
pathway (perhaps dolichol itself) contributes to the development
of ER stress in TGD- or ketoconazole-treated cells (Figure 7). A
prominent role for a perturbing precursor, rather than choles-
terol depletion, is supported by the observation that mevastatin,
which potently activates the SREBPs by blocking cholesterol
biosynthesis at an upstream step, did not significantly activate
the ISR (Figures 6B and 6C), whereas ketoconazole and
RO 48-8071, inhibitors that act downstream of the farnesyl-
pyrophosphate branch point, did induce an ISR (Figure 5A and
data not shown). Furthermore, we were unable to suppress
TGD-mediated ISR activation by supplementing the culture me-
dia with cholesterol. However, we cannot be sure that newly
synthesized cholesterol and that taken up from the media equil-
ibrate identically through cellular compartments, and it is thus
possible that exogenous cholesterol is unable to fully rescue
a deficiency at a relevant intracellular site. Furthermore, the tox-
icity of mevastatin, which precluded high doses and lengthy
treatment, limits our ability to draw conclusions regarding the
role of cholesterol depletion itself in ISR activation. Either way,
a perturbation of the ER likely plays a role in ISR activation fol-
lowing inhibition of CYP51. Surprisingly, deletion of the only
known ER-stress-inducible eIF2a kinase, PERK, did not abolish
eIF2a phosphorylation in compound-treated cells, indicating
that ISR activation is not due exclusively to PERK activity. How-
ever, none of the other three known eIF2a kinases could be im-
plicated in the process, suggesting that the compoundmay also
act through additional mechanisms that remain to be worked
out.
This inquiry led to the identification of a second unsuspected
feature of the relationship between the ISR and sterol metabo-
lism: In wild-type cells, sterol-regulated target-gene induction
decreased at higher compound concentrations, reciprocating
the induction of the ISR. This biphasic profile was not observed
in mutant eIF2aS51A cells with a blocked ISR; in these cells, the
induction of sterol-regulated target genes increased monotoni-
cally with compound dose. This reciprocal relationship of the
ISR and sterol-regulated target-gene expression was reflected
by changes in SREBP activation, which was attenuated atCELL METABOLISM : DECEMBER 2005
CYP51 inhibition and the ISRcompound doses that activate the ISR. Furthermore, artificial
activation of the ISR by a ligand-controlled eIF2a kinase directly
attenuated gene expression and SREBP activation, indepen-
dently of other cell stress pathways.
Phosphorylation of eIF2a attenuates protein synthesis, and
the ISR may deplete cells of a labile factor required for sterol-
regulated gene expression. However, SREBP inhibition is ob-
served at rather modest reductions in global protein synthesis
(data not shown); therefore, we regard it as more likely that the
interaction of the two pathways is mediated by an ISR target
gene (or genes). Thesemay encode direct repressors of SREBP;
alternatively, the ISRmay affect SREBP activation indirectly—by
altering ER membrane lipid composition, for example (Figure 7).
It is notable in this regard that, whereas membrane cholesterol
content is the primary regulator of SREBP’s activity in mamma-
lian cells, fatty acids can contribute to sterol repression (Thewke
et al., 1998; Hannah et al., 2001), and several genes involved in
fatty-acid biosynthesis are targets of the ISR (Harding et al.,
2003). The relatively long latency of ISR-mediated repression
ofSREBP favors, inour opinion, ametabolite-basedmechanism.
In addition to coupling client-protein load to the functionality
of the ER’s protein-handling machinery, the UPR also has an im-
portant role in regulating the cell’s lipid composition. This is re-
flected in the inositol auxotrophy of IRE1mutations in yeast (Cox
et al., 1997) and in the regulation of phospholipid biosynthesis in
mammalian cells by XBP-1 (Sriburi et al., 2004). Furthermore,
the enzymes that process and activate the SREBPs are also uti-
lized for activating ATF6 in response to an unfolded client-
protein load (Haze et al., 1999; Ye et al., 2000). Thus, the lipid-
based and protein-based ER-centered stress responses likely
diverged from a common ancestral pathway. Given the influ-
ence of cholesterol metabolism on ER function, it is tempting
to speculate that ISR-mediated attenuation of SREBP fine tunes
the flux of metabolites through the cholesterol biosynthetic
pathway in response to the needs of ER-stressed cells.
It has recently been found that chronic ER stress in liver and
fat accompanies the metabolic syndrome of obesity and insulin
resistance (Ozcan et al., 2004). Therefore, the inhibitory effect of
the ISR on SREBP-mediated gene expression could affect cho-
lesterol and lipid metabolism in this disorder. It is interesting to
note in this regard that, when placed on a high-fat diet, hetero-
zygous eIF2aS51A/+ mice have elevated serum cholesterol lev-
els, consistent with our finding of defective SREBP repression
by the ISR (Scheuner et al., 2005). The pathophysiological con-
sequences of SREBP activation by the ISR thus need to be ex-
plored in further detail.
Experimental procedures
Cell culture
HT22 cells were cultured in standard medium (DMEM supplemented with
10% fetal clone II serum [Hyclone], penicillin-streptomycin, l-glutamine).
Mouse fibroblast cell lines with defined genotypes of wild-type, Perk2/2 (Har-
ding et al., 2000b), Gcn22/2 (Harding et al., 2000a), Pkr2/2 (Abraham et al.,
1999), Hri2/2 (Han et al., 2001), and homozygous eIF2aS51A (Scheuner et al.,
2001) cells were grown in complete medium (the above medium supple-
mented with MEM nonessential amino acids and 55 mM b-mercaptoethanol).
CHO-KI cells were grown in Hams F12 supplemented with 10% fetal clone II
serum (Hyclone), penicillin-streptomycin, and l-glutamine.
Screening for ISR-activating compounds
The 3000-compound space-filling combinatorial library has been previously
described (Moon et al., 2002; Khersonsky et al., 2003).CELL METABOLISM : DECEMBER 2005For primary and secondary screening, CHO-KI cells stably transfected
with a CHOP::luciferase reporter gene (the coding sequence of CHOP::GFP
[Novoa et al., 2001] was replaced by luciferase) were plated at a density of
2 3 104 cells per well in 96-well plates 24 hr before adding fresh media con-
taining 10 mM of compound in DMSO vehicle. Sixteen hours later, cells were
washed twice and lysed in 25 ml lysis buffer (25 mM gly-gly, 15 mM MgSO4,
4 mM EGTA, 1% Triton X-100, and 1 mM DTT [added fresh]), and luciferase
activity wasmeasured following the addition of 25 ml assay buffer (25mMgly-
gly, 15mMMgSO4, 4mMEGTA, 1%Triton X-100, 11.7mMpotassium phos-
phate, 1.6mMATP, 0.2mg/ml coenzyme A, 500 mM luciferin, and 2mMDTT).
After screening 3000 compounds, 13 were identified as activating the re-
porter 1.1-fold or greater at 10 mM and 8 of these activated the reporter
1.5- to 3.6-fold at 20 mM in secondary screening. Benzoyl-modified versions
of the four best compounds were synthesized, and two of these reproducibly
induced the CHOP::luciferase reporter in a dose-responsive manner.
Protein detection
Cultured cells were treated for 4–16 hr with 25 mM sodium arsenite, 2 mg/ml
tunicamycin, or 35 mM TGD45BZ or as indicated by the figure legends. Cyto-
plasmic and nuclear extracts were made as previously described (Lu et al.,
2004b). To detect SREBP2, whole-cell extracts weremade by collecting cells
in PBS-EDTA and lysing them by three cycles of freeze thaw in whole-cell-
extract buffer (10 mM HEPES [pH 8.0], 50 mM NaCl, 0.5 M sucrose, 0.1 M
EDTA, 0.5% Triton X-100) supplemented just before use with 1 mM dithio-
threitol (DTT), 2 mg/ml pepstatin, 4 mg/ml aprotinin, and 100 mM PMSF.
The lysates were cleared by centrifugation at 425 3 g (2000 rpm) for
10 min at 4ºC in a tabletop centrifuge. The supernatant was transferred to
a new tube, the nuclear pellet was centrifuged at 20,817 3 g (14,000 rpm)
for 15 min at 4ºC, and the two supernatants were pooled. Equal amounts
of protein were loaded per lane (40 mg of cytoplasmic extract, 20 mg of nu-
clear extract, or 75 mg of whole-cell extract), separated, and transferred to ni-
trocellulose. Immunoblotting procedures for PERK, eIF2a, ATF4, GADD34,
and CHOP have previously been described (Harding et al., 2003). SREBP1
and SREBP2 were detected with monoclonal antibodies produced from
the CRL-2121 and CRL-2198 hybridomas (ATCC) and HRP-conjugated
goat anti-mouse secondary antibody.
Radiolabeling of endogenous HSP47with 35S-methionine and cysteine fol-
lowed by immunoprecipitation from cell lysates was as described previously
(Marciniak et al., 2004).
Cell survival assay
Cells were plated at a density of 23 103 per well in 24-well plates. A day later,
the media were replaced with standard medium containing indicated con-
centrations of TGD31BZ, TGD45BZ, ketoconazole, or 1 mM mevastatin.
The cells were incubated with the compound for 14 hr and then exposed
to the indicated concentration of glutamate, tunicamycin, or azetidine-2-
carboxylic acid for an additional 24 hr (glutamate and tunicamycin) or 48 hr
(azetidine-2-carboxylic acid), at which point the cells were washed and
returned to standard media (HT22) or complete medium (all other cell lines).
After an additional 48 hr of culture, the media were replaced with new media
containing 0.05 mg/ml WST-1 (Dojindo) and 0.05 mg/ml phenazine metho-
sulfate (Sigma), and the OD450 minus the OD650 of 100 ml medium from
each well was measured after a 2–4 hr incubation period. The values are
shown as relative to the untreated, which is set to a value of 1 in each graph.
Microarray, Northern blot, and RT-PCR analysis
Total cellular RNA was isolated using the acid phenol/guanidine thiocyanate
method. For array analysis, wild-type or eIF2aS51A mutant cells treated for 0,
8, or 16 hr with 35 mM TGD45BZ and RNA samples were prepared in dupli-
cate for each time point from each cell line. Fluorescently labeled RNA
probes were prepared from each of the 12 samples and hybridized to Affy-
metrix mouse 430A high-density oligonucleotide arrays as previously de-
scribed (Lockhart et al., 1996). Primary image analysis of the arrays was per-
formed using the Genechip 3.2 software package (Affymetrix, Santa Clara,
CA). The raw data from the 12 hybridization experiments were analyzed by
GeneSpring software. Only genes (array spots) whose raw hybridization sig-
nal was significantly above that of the chip background in the treated wild-
type cells (t = 8 and 16 hr) were evaluated (n = 11484). The raw signal strength
from each gene (array spot) was normalized to the mean signal strength of all
genes (array spots) from the same chip to obtain the normalized signal369
A R T I C L Estrength. Then, to allow visualization of all data on the same scale for subse-
quent analysis, the normalized signal strength of each gene (array spot) was
divided by the median signal strength for that gene (array spot) among all 12
samples to obtain the expression level. One hundred and fifty-seven genes
(array spots) were identified as induced 2-fold or more at 8 or 16 hr in wild-
type cells, and 92 genes (array spots) were identified as induced 2-fold or
more in eIF2aS51A cells. Twenty-one genes (array spots) were induced in
both cell types. Fifty-three genes (array spots) that had previously been iden-
tified as being regulated by SREBP proteins were identified, and thirty-eight
of these were induced 1.5-fold or more at 8 or 16 hr in eIF2aS51A cells.
For Northern blot analysis, total cellular RNA was separated on denaturing
agarose gels, transferred to Hybond-N membranes (GE-Amersham), and hy-
bridized to cDNA probes for mouse IDI1 (GenBank accession number
21703725, bp 233–485) or SC4MOL (GenBank accession number 13384835,
bp 487–875) genes isolated by reverse transcription-PCR from fibroblast RNA
or to the previously described cDNA probes for CHOP and GAPDH.
XBP-1 RT-PCRwas carried out using oligo dT priming for the reverse tran-
scriptase reaction using MLV-RT as recommended by the manufacture (Invi-
trogen). Primers XBP.3S (50-AAACAGAGTAGCAGCTCAGACTGC-30) and
XBP.12AS (50-TCCTTCTGGGTAGACCTCTGGGAG-30) were used in a 25 ml
PCR reaction with a single 4 min 94ºC denaturation cycle followed by
30 cycles of 94ºC for 10 s, 63ºC for 30 s, and 72ºC for 30 s followed by sep-
aration of the unprocessed (473 bp) and processed (450 bp) XBP-1 RT-PCR
products on a 10 cm 2% agarose gel.
Lipid analysis
Cultured cells treated with the indicated concentrations of TGD31BZ or me-
vastatin for 24 hr in lipoprotein-deficient medium (complete medium made
with 5% lipoprotein-deficient bovine calf serum [LPDS] instead of the usual
serum and supplemented with 50 mM mevalonic acid). Total cellular lipids
were extracted (Folch et al., 1957), dried under a nitrogen stream, and sapon-
ified in 90% methanol, 10% 10 M KOH for 16 hr at room temperature.
After clearing by centrifugation, the soluble nonsaponifiable lipids were re-
extracted and dried. Cholesterol levels were determined using enzymatic
detection with a kit as directed by the manufacturer (R-Biopharm). For thin-
layer chromatography analysis, [14C]mevalonic acid was prepared from
[14C]mevalonic-acid lactone by alkaline cleavage: The dried compound
(50 mCi) was resuspended in 340 ml 1.2N NaOH and heated for 30 min at
55ºC, then neutralized by the addition of 19 ml 12N HCl and 50 ml 103 PBS.
Cells growing in 10 cm dishes were switched to lipoprotein-deficient medium
for 16 hr before pretreatment for 1 hr with the indicated compounds. The cells
were then labeled with 1.5 mCi [14C]mevalonic acid for 5 hr, washed, and col-
lected by scraping in PBS. The cell pellets were saponified, and the nonsa-
ponifiable lipids were extracted, dried, and then resuspended in 50 ml hexa-
nes:chloroform (70:30) and separated on prescored glass thin-layer
chromatography plates using hexanes:diethyl ether (50:50). The migration
of nonradioactive standards (Sigma) was detected by iodine vapor staining.
Supplemental data
Supplemental Data include Supplemental References, three tables, and four
figures and can be foundwith this article online at http://www.cellmetabolism.
org/cgi/content/full/2/6/361/DC1/.
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